Immunexpress Continues Executive Team Expansion with Addition of Fayyaz Memon as VP of Regulatory Affairs & Quality

SEATTLEJuly 10, 2018 /PRNewswire/ — Immunexpress, Inc. today announced that Fayyaz Memon, MBA, MS, has joined the company’s Executive Team as Vice President of Regulatory Affairs and Quality.

“Mr. Memon arrives at a key time for the Company as we continue to fortify our leadership team with accomplished individuals well-versed in the life sciences industry,” Rolland D. Carlson, PhD, President and Chief Executive Officer of Immunexpress. “Fayyaz’ experience in regulatory affairs on an international level will be of great value to Immunexpress, providing guidance on the process of commercializing our ground-breaking SeptiCyte™ technology to assist physicians and patients on a global scale.”

“It is an exciting time to join Immunexpress as the company is in the process of commercializing SeptiCyte™ LAB not only in the U.S., but also abroad in Europe,” commented Mr. Memon. “Immunexpress is leading the charge to develop a reliable and rapid sepsis diagnostic tool that I believe will have a significant impact on physicians, patients and key healthcare stakeholders.”

Mr. Memon joins Immunexpress with over 25 years of experience in the life sciences industry covering in-vitro diagnostics (IVD), medical devices, and pharmaceutical products. Mr. Memon has served in leadership positions at Asuragen, Qiagen, PrimeraDx, Thermo Fisher Scientific, Digene, SmithKline Beecham, and Johnson & Johnson.  Additionally, he founded a regulatory and quality consulting company, AltaQ, with a focus on molecular diagnostics to bring new and innovative products to market in an efficient and expeditious manner.

Mr. Memon has completed projects spanning multiple countries including the U.S., ChinaJapanFranceGermany, and Italy.  Mr. Memon earned his MBA in Operations and Quality Management and MS in Engineering from Drexel University.

About Immunexpress 

Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients suspected of sepsis. Immunexpress’ SeptiCyte™ technology rapidly quantifies, directly from whole blood, specific molecular markers from the patient’s own immune system – the ‘host response’. SeptiCyte™ LAB, recently cleared by the FDA, is the first of its kind in using the host immune system to differentiate systemic inflammatory response syndrome (SIRS) and sepsis. Detecting the host’s response to infection has the potential to differentiate infection earlier, faster and more accurately than finding the invading pathogen because it is independent of whether or not the pathogen is present in the sample. Immunexpress’ pipeline includes several sample-to-answer assays for near patient testing.

For more information visit http://www.immunexpress.com/.

Follow Immunexpress on Twitter and LinkedIn.

Media Contacts: 
Maggie Beller
Russo Partners, LLC
(646) 942-5631
[email protected]

SOURCE Immunexpress, Inc.